These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 11773166)

  • 1. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Gedlicka C; Schüll B; Brugger S; Schneeweiss B; Lang F; Lenauer A; Depisch D
    J Clin Oncol; 2002 Jan; 20(1):165-72. PubMed ID: 11773166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen.
    Schüll B; Kornek GV; Schmid K; Raderer M; Ulrich-Pur H; Fiebiger W; Schneeweiss B; Lenauer A; Depisch D; Scheithauer W
    Onkologie; 2002 Aug; 25(4):358-62. PubMed ID: 12232488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
    Scheithauer W; Kornek GV; Brugger S; Ullrich-Pur H; Valencak J; Raderer M; Fiebiger W; Kovats E; Lang F; Depisch D
    Cancer Invest; 2002; 20(1):60-8. PubMed ID: 11853004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Kovats E; Schneeweiss B; Lang F; Lenauer A; Depisch D
    J Clin Oncol; 2003 Apr; 21(7):1307-12. PubMed ID: 12663719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial.
    Scheithauer W; Kornek GV; Ulrich-Pur H; Penz M; Raderer M; Salek T; Haider K; Kwasny W; Depisch D
    Cancer; 2001 Apr; 91(7):1264-71. PubMed ID: 11283925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
    Scheithauer W; Kornek GV; Schuell B; Ulrich-Pur H; Penz M; Raderer M; Lang F; Schneeweiss B; Lenauer A; Depisch D
    Ann Oncol; 2001 May; 12(5):709-14. PubMed ID: 11432632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Raltitrexed and oxaliplatin in colorectal cancer: in vitro and in vivo study of a synergistic cytostatic combination].
    Schüll B; Scheithauer W
    Acta Med Austriaca; 2002; 29(4):124-31. PubMed ID: 12424937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
    Ulrich-Pur H; Kornek GV; Fiebiger W; Gedlicka C; Raderer M; Lenauer A; Depisch D; Lang F; Pidlich J; Scheithauer W
    Ann Oncol; 2001 Sep; 12(9):1269-72. PubMed ID: 11697839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.
    Feliu J; Castañón C; Salud A; Mel JR; Escudero P; Pelegrín A; López-Gómez L; Ruiz M; González E; Juárez F; Lizón J; Castro J; González-Barón M;
    Br J Cancer; 2005 Nov; 93(11):1230-5. PubMed ID: 16265344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study.
    Rosati G; Rossi A; Germano D; Reggiardo G; Manzione L
    Anticancer Res; 2003; 23(3C):2981-5. PubMed ID: 12926149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
    Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
    J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma.
    Ford HE; Cunningham D; Ross PJ; Rao S; Aherne GW; Benepal TS; Price T; Massey A; Vernillet L; Gruia G
    Br J Cancer; 2000 Jul; 83(2):146-52. PubMed ID: 10901362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).
    Wöll E; Greil R; Eisterer W; Bechter O; Fridrik MA; Grünberger B; Zabernigg A; Mayrbäurl B; Russ G; Dlaska M; Obrist P; Thaler J
    Anticancer Res; 2011 Dec; 31(12):4439-43. PubMed ID: 22199312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
    Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
    J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
    Ulrich-Pur H; Raderer M; Verena Kornek G; Schüll B; Schmid K; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Scheithauer W
    Br J Cancer; 2003 Apr; 88(8):1180-4. PubMed ID: 12698181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study.
    Aparicio J; Vicent JM; Maestu I; Bosch C; Galán A; Busquier I; Llorca C; Garcerá S; Campos JM; López-Tendero P; Balcells M
    Oncology; 2005; 68(1):58-63. PubMed ID: 15809521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
    Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
    J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
    Calvo E; Cortés J; Rodríguez J; Fernández-Hidalgo O; Rebollo J; Martín-Algarra S; García-Foncillas J; Martínez-Monge R; de Irala J; Brugarolas A
    Clin Colorectal Cancer; 2002 Aug; 2(2):104-10. PubMed ID: 12453325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.